Role of Activin A in the Pathogenesis of Endothelial Cell Dysfunction in Preeclampsia

Author(s):  
Sebastian R. Hobson ◽  
Rebecca Lim ◽  
Joanne C. Mockler ◽  
Seshini Gurusinghe ◽  
Euan M. Wallace
2016 ◽  
Vol 6 (2) ◽  
pp. 130-133 ◽  
Author(s):  
Sebastian R. Hobson ◽  
Rutu Acharya ◽  
Rebecca Lim ◽  
Siow Teng Chan ◽  
Joanne Mockler ◽  
...  

1995 ◽  
Vol 117 (2) ◽  
pp. 179-188 ◽  
Author(s):  
Michal Toborek ◽  
Steven W. Barger ◽  
Mark P. Mattson ◽  
Craig J. McClain ◽  
Bernhard Hennig

2014 ◽  
Vol 21 (1) ◽  
pp. 26-37 ◽  
Author(s):  
Enrique Guzmán-Gutiérrez ◽  
Pablo Arroyo ◽  
Rocío Salsoso ◽  
Bárbara Fuenzalida ◽  
Tamara Sáez ◽  
...  

Shock ◽  
2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Antony Leonard ◽  
Pei Yi Su ◽  
David I. Yule ◽  
Arshad Rahman ◽  
Fabeha Fazal

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Theresa C. Barnes ◽  
Marina E. Anderson ◽  
Robert J. Moots

Interleukin-6 is currently attracting significant interest as a potential therapeutic target in systemic sclerosis (SSc). In this paper, the biology of interleukin-6 is reviewed, and the evidence for interleukin-6 dysregulation in SSc is explored. The role of inteleukin-6 classical and trans signalling pathways in SSc relevant phenomena such as chronic inflammation, autoimmunity, endothelial cell dysfunction, and fibrogenesis is discussed. The existing evidence that interventions designed to block interleukin-6 signalling are of therapeutic relevance in SSc is evaluated.


2008 ◽  
Vol 22 (S1) ◽  
Author(s):  
Ayako Makino ◽  
Oleksandr Platoshyn ◽  
Jorge Suarez ◽  
Jason X.‐J. Yuan ◽  
Wolfgang H. Dillmann

Sign in / Sign up

Export Citation Format

Share Document